

Ad hoc announcement

Marinomed Biotech AG signs agreement for sale of Carragelose business to French Unither Pharmaceuticals

Korneuburg, Austria, November 26, 2024 – Marinomed Biotech AG (the “Company”) announces the signing of an agreement for the sale of its Carragelose business to French Unither Pharmaceuticals (“Unither”), a leading contract development and manufacturing organization (CDMO) of medical devices and pharmaceutical products. The contract provides for upfront and milestone payments of total up to EUR 20 million, depending on the achievement of defined commercial and operational targets, over the next two years. As part of the agreement, Marinomed and Unither intend to enter into a transition service agreement at completion of such transaction. The proceeds from the sale of the Carragelose business are planned to finance both the operating business, with increased focus on the Marinosolv platform, and the restructuring plan agreed upon with the Company’s creditors on November 14, 2024. The closing of the contract is *inter alia* subject to the successful completion of the restructuring proceedings, the approval by the Company’s Supervisory Board and shareholders at an extraordinary general meeting.

+++ End of ad-hoc announcement +++

About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline and globally marketed therapeutics. The Company develops innovative patent-protected products in the therapeutic areas immunology and virology based on the platform Marinosolv® and the virus-blocking activity of Carragelose®. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The virology segment includes Carragelose®-based over-the-counter (OTC) products to prevent and treat respiratory viral infections that are partnered in more than 40 countries. The Company is headquartered in Korneuburg, Austria, and is listed on the prime market of the Vienna Stock Exchange (VSE:MARI). For further information, please visit: <https://www.marinomed.com>

For further inquiries contact:

Marinomed Biotech AG

PR: Lucia Ziegler

T: +43 2262 90300 158

E-Mail: pr@marinomed.com

E-Mail: ir@marinomed.com

Disclaimer

This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ

materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as "anticipate," "believe", "estimate", "expect", "intend", "plan", "project" and "target". Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed, Marinosolv® and Carragelose® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only.